Last reviewed · How we verify

NCT04345640

The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.

Status unknown Last updated 3 September 2020
What this trial tests

trial testing no intervention in Liver Cirrhoses in 1,000 participants. Status unknown.

Timeline
10 April 2020
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorInstitute of Liver and Biliary Sciences, India
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date10 April 2020
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 70, any sex, with Liver Cirrhoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).
    Sarin SK, Choudhury A, Lau GK, Zheng MH, et al · · 2020 · cited 200× · PMID 32623632 · DOI 10.1007/s12072-020-10072-8
  2. Pre-Existing Liver Disease Is Associated with Poor Outcome in Patients with SARS CoV-2 Infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
    Sarin SK, Choudhury A, Lau G, Zheng M, et al · · 2020 · DOI 10.2139/ssrn.3611970
  3. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
    Sarin SK, Choudhury A, Lau GK, Zheng M, et al · · 2020 · DOI 10.21203/rs.3.rs-36338/v1

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Liver Cirrhoses

Currently open trials in the same condition.

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04345640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing